Eli Lilly's new obesity drug shows promising results in weight loss, surpassing its existing drug Zepbound, as competition in ...

I'm a board-certified endocrinologist and , contrary to popular belief, choosing GLP-1 treatment isn't the ' easy way out.' ...

ReBoost Nasal Spray has been recalled nationwide after tests found mold and bacteria, prompting FDA warnings of possible serious infections.

Eli Lilly's new drug outperforms its predecessor in weight loss, the weight-loss drug market is expected to surge, Johnson & ...

Researchers adjusted for confounders like age, hypertension, cardiovascular disease, and other comorbidities. The refined results indicated GLP-1 users had a 16% lower risk of developing epilepsy ...

The World Health Organization issued new guidance this week on the use of popular GLP-1 drugs, like Ozempic, Wegovy, Mounjaro ...

No matter what happens to the industry, though, there are plenty of excellent healthcare stocks that look attractive heading into the new year. Let's consider three that are among my favorites to buy: ...

The company ended the third quarter of 2025 with $715 million in cash, a war chest deemed sufficient to fund both ongoing VANQUISH trials to completion. Research and development expenses jumped to $90 ...